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ABOUT THE COVER
The cover shows head and neck squamous cell carcinoma (UMSCC1) xenograft tissue sections
harvested after treatment with the dual PI3k/mTOR inhibitor PF-05212384. Immunohistochemical
staining demonstrates a significant reduction in phospho-S6 fluorescence (green) with intravenous
PF-05212384 treatment. For details, see the article by Leiker and colleagues on page 2792 of this
issue.
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